Jeffrey Zwicker, MD
Hematology · New York, NYNPI 1851330849
Payments from drug & device makers
Across 326 payments — averaging $3949.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$472K
- Acerta Pharma LLC$213K
- Regeneron$154K
- Novartis$139K
- Merck$128K
- Astrazeneca UK Limited$77K
- plus $104K from 12 others
Across 124 payments — averaging $2690.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$182K
- Pharmacyclics LLC, An Abbvie Company$78K
- Janssen Research & Development, LLC$22K
- Verastem, Inc.$13K
- Secura Bio, Inc.$10K
- Beigene, Ltd.$9K
- plus $19K from 4 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 99 | $471,690 |
| Acerta Pharma LLC | 24 | $213,100 |
| Regeneron | 83 | $154,090 |
| Novartis | 4 | $138,881 |
| Merck | 25 | $128,438 |
| Astrazeneca UK Limited | 32 | $77,155 |
| Eisai Inc. | 11 | $38,700 |
| E.r. Squibb & Sons, L.L.C. | 11 | $16,329 |
| CSL Behring | 5 | $15,775 |
| Sanofi US Services Inc. | 5 | $11,492 |
| Bristol Myers Squibb | 12 | $11,450 |
| Pfizer | 5 | $3,259 |
| Dova Pharmaceuticals | 1 | $3,000 |
| Portola Pharmaceuticals, LLC | 3 | $1,865 |
| AstraZeneca | 1 | $1,220 |
| Amgen | 3 | $988 |
| Octapharma USA, Inc. | 1 | $49 |
| Agios Pharmaceuticals, Inc. | 1 | $17 |
How this compares
$1,287,497 in reported general payments places this provider in the 90th percentile of 157 hematology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology in New York
- Michael MauroNew York$34.9M
- Adam KittaiNew York$8.2M
- Barry CollerNew York$7.9M
- Ran ReshefNew York$5.4M
- Divaya BhutaniNew York$4.8M
- Richard FurmanNew York$3.1M
- Joseph JurcicNew York$1.7M
- Marissa RybsteinNew York$1.6M
- Allyson OceanNew York$1.5M
- Mark HeaneyNew York$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.